METHOD OF CREATING TARGET PANEL FOR STUDYING GENOMIC REGIONS FOR DETECTING THERAPEUTIC BIOMARKERS OF IMMUNE CHECKPOINT (IC) INHIBITORS Russian patent published in 2024 - IPC C12Q1/686 C12Q1/6874 C40B50/06 

FIELD: biotechnology.

SUBSTANCE: described is a method of creating a target panel for investigating target genomic regions to identify predictive genetic biomarkers of potential effectiveness and/or resistance to immune checkpoint (CI) inhibitors. Method involves genetic analysis of resection or biopsy material of tumor tissue of patient with diagnosed malignant neoplasm (MNP) before the beginning of the course or during immunotherapy based on immune checkpoint inhibitors—anti-PD-l or anti-PD-L1 preparations, namely: laboratory extraction of DNA from a sample of tumor material, measurement of concentration of extracted DNA, preparation of DNA libraries using tumor DNA as a matrix for amplification of target genomic regions during PCR with specific primers, sequencing of DNA libraries, subsequent bioinformatic processing of sequencing results, interpretation of biological and clinical significance of genetic variants detected by results of targeted sequencing, identification of predictive genetic biomarkers of potential efficacy and/or resistance to immunotherapy with immune checkpoint inhibitors based on target genome regions including coding sequences of 34 genes: JAK3, JAK2, MDM2, CD274, PBRM1, B2M, ERBB2, IFNGR1, CD8A, JAK1, MET, BAP1, POLE, POLD1, EGFR, LAG3, BRAF, HAVCR2, MLH1, KRAS, IFNG, ALK, PIK3CA, IDO1, AXL, TP53, STATI, SMAD4, ROS1, ARID1A, PTEN, PDCD1LG2, STK11, VHL), as well as sections of 9p24.1 locus: genes JAK2, PD-L1, and PD-L2 and intergenic regions.

EFFECT: invention can be used for selection of anticancer therapy or determination of its possible effectiveness.

12 cl, 5 tbl